<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02288364</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00056728</org_study_id>
    <nct_id>NCT02288364</nct_id>
  </id_info>
  <brief_title>Reducing Pain of Lidocaine Injection</brief_title>
  <official_title>Does Sodium Bicarbonate Reduce the Pain of Lidocaine for Local Anesthesia in Percutaneous Breast Biopsies?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the benefit, if any, of buffering lidocaine (adding
      sodium bicarbonate) when used for local anesthesia prior to percutaneous breast needle core
      biopsies. The medicine doctors use to reduce the pain of breast biopsies, lidocaine, can
      cause pain for approximately 15 seconds until the numbing effect begins. It is possible that
      this pain is caused because lidocaine is acidic. Some physicians believe that reducing the
      acidity of lidocaine by mixing it with sodium bicarbonate will reduce the initial pain of
      injecting the lidocaine. Both approaches - injecting 1% lidocaine alone and injecting 1%
      lidocaine mixed with sodium bicarbonate - are used as routine standard of care by
      radiologists today. The purpose of this study is to determine if either approach is more
      comfortable for patients having breast procedures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately prior to anesthetizing, within approximately 1 minute of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately on completion of anesthetizing the skin, within approximately 1 minute of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately on completion of anesthetizing the parenchyma (deeper breast tissue), within approximately 4 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately on completion of the biopsy, within approximately 20 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>30 seconds after initiating superficial injection in the subcutaneous tissue, within approximately 1 minute of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately prior to injection of &quot;deep&quot; anesthesia in the breast parenchyma, within approximately 4 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>30 seconds after initiating deep injection of the parenchyma (deeper breast tissue), within approximately 4 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately prior to obtaining the first core biopsy specimen, within approximately 15 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately after obtaining the first core biopsy specimen, within approximately 15 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>immediately on completion of the final core biopsy specimen, within approximately 20 minutes of starting</time_frame>
    <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Pain of Anesthesia at Breast Biopsy</condition>
  <arm_group>
    <arm_group_label>1% Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% Lidocaine alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% Lidocaine plus sodium bicarbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine</intervention_name>
    <arm_group_label>1% Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Lidocaine plus sodium bicarbonate</intervention_name>
    <arm_group_label>1% Lidocaine plus sodium bicarbonate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21 Years of age

          -  Any patient scheduled for a breast biopsy at Duke Breast Interventional Imaging

        Exclusion Criteria:

          -  Less than 21 Years of age

          -  Allergic to Lidocaine or Sodium Bicarbonate

          -  Not mentally capable of consenting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jay A Baker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2014</study_first_posted>
  <results_first_submitted>February 16, 2016</results_first_submitted>
  <results_first_submitted_qc>February 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 14, 2016</results_first_posted>
  <last_update_submitted>March 16, 2016</last_update_submitted>
  <last_update_submitted_qc>March 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>88 participants signed consent. 86 participants were randomized.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>1% Lidocaine</title>
          <description>1% Lidocaine alone.</description>
        </group>
        <group group_id="P2">
          <title>1% Lidocaine Plus Sodium Bicarbonate</title>
          <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1% Lidocaine</title>
          <description>1% Lidocaine alone.</description>
        </group>
        <group group_id="B2">
          <title>1% Lidocaine Plus Sodium Bicarbonate</title>
          <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="42"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="86"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.26" spread="13.70"/>
                    <measurement group_id="B2" value="53.80" spread="13.22"/>
                    <measurement group_id="B3" value="53.53" spread="13.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately prior to anesthetizing, within approximately 1 minute of starting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" spread="1.92"/>
                    <measurement group_id="O2" value="0.56" spread="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately on completion of anesthetizing the skin, within approximately 1 minute of starting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.07" spread="2.05"/>
                    <measurement group_id="O2" value="1.61" spread="1.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately on completion of anesthetizing the parenchyma (deeper breast tissue), within approximately 4 minutes of starting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.98" spread="2.67"/>
                    <measurement group_id="O2" value="2.02" spread="2.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately on completion of the biopsy, within approximately 20 minutes of starting</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="2.65"/>
                    <measurement group_id="O2" value="0.91" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>30 seconds after initiating superficial injection in the subcutaneous tissue, within approximately 1 minute of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately prior to injection of “deep” anesthesia in the breast parenchyma, within approximately 4 minutes of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>30 seconds after initiating deep injection of the parenchyma (deeper breast tissue), within approximately 4 minutes of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately prior to obtaining the first core biopsy specimen, within approximately 15 minutes of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately after obtaining the first core biopsy specimen, within approximately 15 minutes of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
        <time_frame>immediately on completion of the final core biopsy specimen, within approximately 20 minutes of starting</time_frame>
        <population>Data not collected at this time point.</population>
        <group_list>
          <group group_id="O1">
            <title>1% Lidocaine</title>
            <description>1% Lidocaine alone.</description>
          </group>
          <group group_id="O2">
            <title>1% Lidocaine Plus Sodium Bicarbonate</title>
            <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Measure of pain on a scale of 0-10. Zero would indicate no pain while a score of 10 would be the worse pain possible.</description>
          <population>Data not collected at this time point.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1% Lidocaine</title>
          <description>1% Lidocaine alone.</description>
        </group>
        <group group_id="E2">
          <title>1% Lidocaine Plus Sodium Bicarbonate</title>
          <description>1% Lidocaine plus 8.4% sodium bicarbonate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jay A. Baker, MD</name_or_title>
      <organization>Duke University Medical Center</organization>
      <phone>919-684-7645</phone>
      <email>jay.baker@duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

